When people talk about the cost of GLP-1 medications, the conversation usually centers on the drugs themselves.

Our latest analysis suggests something different: what patients pay often depends less on the medication than on the label attached to it.

By analyzing more than 165,000 insurance verification transactions processed on the Infinitus platform in 2026, we found a striking pattern: medications labeled for diabetes are consistently covered far more generously than medications labeled for weight management, even when the underlying molecule is remarkably similar.

What it means: The label matters

Among the transactions we analyzed:

  • Wegovy carried a median patient out-of-pocket cost of $149 per fill.
  • Ozempic and Mounjaro, both labeled for diabetes, typically cost patients $25-$30 per fill.
  • Nearly 42% of weight-loss-labeled claims were paid through fixed manufacturer pricing programs, compared with just 16% of diabetes-labeled claims, suggesting patients seeking obesity treatment rely much more heavily on coupons and manufacturer assistance rather than traditional insurance coverage.

One important nuance also emerged: Not every weight-loss medication behaves the same way. Zepbound had a median patient cost of roughly $35 per fill, much closer to diabetes-labeled drugs than Wegovy. That suggests coverage decisions vary considerably across products and manufacturers, rather than creating a single “weight-loss drug” category.

A coverage story, not just a pricing story

Taken together, these findings point toward something larger than individual drug prices.

They suggest the healthcare system continues to reimburse treatment of established disease more consistently than treatment aimed at preventing disease progression or managing obesity, even when the medications share similar clinical foundations.

For patients, that difference can determine whether a prescription is affordable, delayed, or abandoned altogether.

For manufacturers, it can create additional complexity navigating benefits, prior authorizations, manufacturer assistance programs, and patient education.

Methodology

This analysis is based on 165,000 automated insurance verification transactions processed through the Infinitus platform in 2026. The dataset captures transaction-level information including patient copay requirements, annual out-of-pocket maximums, and drug mix. Findings were benchmarked against publicly available data from CMS, Eli Lilly, Novo Nordisk, and the CDC.

Important note: Drugs in this analysis were classified according to their FDA-approved label, not the patient’s diagnosis or reason for use. The findings therefore reflect differences in how labeled products are covered, rather than why any individual patient received a medication.